Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
News
10/17/2025
Recent Executive Moves
10/17/2025
LEO Pharma's Anzupgo Cream NDA Accepted in China
10/17/2025
Gilead's Kite Strikes Up to $1.64B In Vivo CAR-T Deal with China's Pre...
10/17/2025
RemeGen's Telitacicept Demonstrates Strong Phase 3 Efficacy in Lupus, ...
10/17/2025
Dianthus Secures Exclusive Global Rights to DNTH212 from China's Leads...
10/17/2025
Roche Expands Oncology Pipeline Thru Global Licensing Deal with Hansoh...
10/17/2025
I-Mab to Rebrand as NovaBridge Biosciences and Pursue Hong Kong IPO
10/16/2025
NHC Holds High-Level Meetings with Abbott and Roche to Advance Healthc...
10/16/2025
China NMPA Cancels 80 Drug Registration Certificates, Including Lorata...
10/16/2025
Belite Bio Secures Priority Review from China's NMPA for Tinlarebant
10/16/2025
Kailera Launches with $600M Series B to Advance GLP-1 Portfolio Acqui...
10/16/2025
Xuanzhu Bio Soars on Hong Kong Debut After Highly Oversubscribed IPO
10/16/2025
Qilu Presents Promising Phase I Data for AR PROTAC Degrader QLH12016
10/15/2025
Sino Biopharma's TQB2102 Receives Breakthru Therapeutic Designation in...
10/15/2025
Pfizer CEO Calls for Greater U.S.–China Collaboration in Biopharma In...
10/14/2025
GSK's Shingrix Wins Chinese Approval for Expanded Use
10/14/2025
Biokin and SystImmune Present Promising Early Data for EGFR×HER3 Bisp...
10/14/2025
Multitude Reports Updated Safety and Dose Findings for AMT-116 at ESMO...
10/14/2025
AskBio Reports Promising Safety Results from First Cohort of AB-1003 G...
10/13/2025
Huadao Secures Over CNY 100M in Series D+2 Financing to Advance CAR-T ...
10/13/2025
Lepu Reports Early Clinical Data for ADC Programs in Various Cancers
10/13/2025
Hansoh Pharma Reports Phase II Data for Oral B7H3 ADC HS-20093
10/13/2025
Lundbeck's Epilepsy Drug Bexicaserin Granted Breakthrough Therapy Stat...
10/13/2025
Two Decades of Pediatric Drug Trials in China Reveal Progress and Pers...
10/13/2025
CDE Seeks Input on Draft Technical Requirements for Sodium Iodide [131...
10/13/2025
CDE Solicits Comments on Draft Guidelines for Bioequivalence Risk Asse...
10/13/2025
CDE Issues Guidance to Address Common Challenges in Pediatric Drug Dev...
10/13/2025
China Introduces New Regulations to Govern Clinical Research and Appli...
10/13/2025
AviadoBio and UgeneX Enter Exclusive Option-License Deal to Develop Op...
10/13/2025
Huadao Bio Secures Over CNY 100M in Series D+2 Financing
Page:
10
/
58
Total number of articles:
1720
:
[First]
[<<]
[8]
[9]
[10]
[11]
[12]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit